N-Ethyl-3,5-dimethylmorpholin | 45739-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-Ethyl-3,5-dimethylmorpholin
• 英文别名: 4-ethyl-3,5-dimethyl-morpholine；4-Ethyl-3,5-dimethylmorpholine
• CAS: 45739-34-2
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: RTNQIJRVUFPGOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吗啉,3,5-二甲基- 、 溴乙烷 生成 N-Ethyl-3,5-dimethylmorpholin
  参考文献：
  名称：

  Maillard,J. et al., Chimica Therapeutica, 1969, vol. 4, p. 80 - 88

  摘要：

  DOI：

文献信息

• AMINO ACID COMPOUNDS AND METHODS OF USE
  申请人：Pliant Therapeutics, Inc.

  公开号：US20200109141A1

  公开（公告）日：2020-04-09

  The invention relates to compounds of formula (I): or a salt thereof, wherein R 1 , G, L 1 , L 2 , L 3 , and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ 1 integrin and αvβ 6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及如下公式(I)的化合物： 或其盐，其中R1、G、L1、L2、L3和Y如本文所述。公式(I)的化合物及其药物组合物是αvβ1整合素和/或αvβ6整合素的一种或两种的抑制剂，用于治疗纤维化，如非酒精性脂肪肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• [EN] CTPS1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CTPS1 ET LEURS UTILISATIONS
  申请人：NIMBUS CLOTHO INC

  公开号：WO2022087634A1

  公开（公告）日：2022-04-28

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CPTS1, and the treatment of CPTS1-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们抑制CPTS1和治疗CPTS1介导的疾病的方法。
• Coating composition for precoated metal material
  申请人：NIPPON PAINT CO., LTD.

  公开号：EP0448341A1

  公开（公告）日：1991-09-25

  Disclosed is a coating composition for precoated metal material excellent in electrodeposition coating performance, possessing high corrosion-resistance and high processing adhesion, and capable of forming a coat film applicable to spot welding. The coating composition for precoated metal material in the present invention comprises, as essential ingredients, a binder resin possessing film-forming capability, a hydrophilic resin for performing electrodeposition coating uniformly, and fine granular silica for enhancing corrosion-resistance, being dissolved or dispersed in organic solvent, is characterized in that the binder resin has a number-average molecular weight of 600 to 100,000 and contains 25 or more mol% of an aromatic hydroxy compound in its constituent monomer, and the hydrophilic resin is a polyamine resin and/or polyimine resin having a number-average molecular weight of 600 to 100,000 and contains 25 or more mol% of an amine compound in its constituent monomer.

  本发明公开了一种用于预涂覆金属材料的涂料组合物，它具有优异的电沉积涂覆性能、高耐腐蚀性和高加工附着力，并能形成适用于点焊的涂膜。 本发明中用于预涂金属材料的涂料组合物包括作为基本成分的具有成膜能力的粘结剂树脂、用于均匀进行电沉积涂覆的亲水性树脂和用于提高耐腐蚀性的细颗粒状二氧化硅，它们溶解或分散在有机溶剂中、其特征在于，粘合剂树脂的数均分子量为 600 至 100 000，在其组成单体中含有 25 或 25 mol%以上的芳香族羟基化合物，亲水性树脂是数均分子量为 600 至 100 000，在其组成单体中含有 25 或 25 mol%以上的胺化合物的聚胺树脂和/或聚亚胺树脂。
• Substituted amino acids as integrin inhibitors
  申请人：Pliant Therapeutics, Inc.

  公开号：US11180494B2

  公开（公告）日：2021-11-23

  The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ1 integrin and αvβ6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及式 (I) 化合物： 或其盐，其中 R1、G、L1、L2、L3 和 Y 如本文所述。式（I）化合物及其药物组合物是αvβ1整合素和αvβ6整合素中一种或两种的抑制剂，可用于治疗纤维化，如非酒精性脂肪性肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• AMINOAMIDE COMPOUNDS
  申请人：BioTheryX, Inc.

  公开号：US20210145812A1

  公开（公告）日：2021-05-20

  Compounds with amino amide linkers and pharmaceutical compositions and medicaments comprising such compounds are disclosed. In addition, methods of making such compounds and their uses for treating or ameliorating diseases, disorders, or conditions associated with protein malfunction, such as cancer, are provided.